SYK · Stryker Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.02B | - | $6.06B | $6.02B | $5.87B | - | $5.49B | $5.42B | $5.24B | - |
| Cost of Revenue | $2.21B | - | $2.21B | $2.18B | $2.12B | - | $1.98B | $2.01B | $1.91B | - |
| Gross Profit | $3.81B | - | $3.85B | $3.84B | $3.74B | - | $3.52B | $3.42B | $3.33B | - |
| R&D | $413.00M | - | $410.00M | $407.00M | $405.00M | - | $377.00M | $363.00M | $368.00M | - |
| SG&A | $2.28B | - | $2.04B | $2.08B | $2.30B | - | $1.90B | $1.85B | $1.84B | - |
| Total Operating Expenses | $2.87B | - | $2.72B | $2.73B | $2.91B | - | $2.43B | $2.37B | $2.36B | - |
| D&A | $397.00M | - | $371.00M | $354.00M | $355.00M | - | - | - | $107.00M | - |
| Operating Income | $936.00M | - | $1.14B | $1.11B | $837.00M | - | $1.08B | $1.05B | $972.00M | - |
| Interest Expense | $142.00M | - | $157.00M | $96.00M | - | - | - | - | - | - |
| Income Tax | $105.00M | - | $170.00M | $132.00M | $110.00M | - | $209.00M | $173.00M | $135.00M | - |
| Net Income | $745.00M | - | $859.00M | $884.00M | $654.00M | - | $834.00M | $825.00M | $788.00M | - |
| EPS - Basic | $1.95 | - | $2.25 | $2.32 | $1.71 | - | $2.18 | $2.17 | $2.07 | - |
| EPS - Diluted | $1.93 | - | $2.22 | $2.29 | $1.69 | - | $2.16 | $2.14 | $2.05 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.88B | $4.01B | $3.26B | $2.38B | $2.32B | $3.65B | $3.85B | $1.87B | $2.33B | $2.97B |
| Accounts Receivable | $3.57B | $4.04B | $3.64B | $3.92B | $3.96B | $3.99B | $3.74B | $3.62B | $3.47B | $3.77B |
| Inventory | $5.42B | $5.31B | $5.37B | $5.29B | $5.11B | $4.77B | $5.29B | $5.04B | $5.03B | $4.84B |
| Accounts Payable | $1.59B | $1.80B | $1.50B | $1.44B | $1.46B | $1.68B | $1.34B | $1.30B | $1.25B | $1.52B |
| Current Assets | $13.34B | $14.76B | $13.71B | $13.00B | $13.02B | $14.85B | $14.67B | $11.64B | $11.89B | $12.52B |
| Total Assets | $46.29B | $47.84B | $47.06B | $46.33B | $46.01B | $42.97B | $43.83B | $39.13B | $39.40B | $39.91B |
| Current Liabilities | $6.32B | $7.79B | $7.41B | $7.29B | $7.93B | $7.62B | $7.67B | $6.93B | $6.96B | $7.92B |
| Long-term Debt | $14.22B | $14.86B | $14.85B | $14.83B | $14.38B | $12.19B | $13.32B | $10.13B | $10.81B | $10.90B |
| Total Liabilities | $23.31B | $25.42B | $25.27B | $25.14B | $25.08B | $22.34B | $23.68B | $19.37B | $20.23B | $21.32B |
| Stockholders' Equity | $22.98B | $22.42B | $21.79B | $21.19B | $20.93B | $20.63B | $20.15B | $19.76B | $19.17B | $18.59B |
| Retained Earnings | $20.88B | $20.47B | $19.96B | $19.42B | $18.86B | $18.53B | $18.30B | $17.77B | $17.25B | $16.77B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $581.00M | - | - | - | $250.00M | - | - | - | $204.00M | - |
| Investing Cash Flow | ($185.00M) | - | - | - | ($4.14B) | - | - | - | ($408.00M) | - |
| Financing Cash Flow | ($1.51B) | - | - | - | $2.53B | - | - | - | ($418.00M) | - |
| CapEx | $166.00M | - | - | - | $123.00M | - | - | - | $167.00M | - |
| Free Cash Flow | $415.00M | - | - | - | $127.00M | - | - | - | $37.00M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 63.3% | - | 63.6% | 63.8% | 63.8% | - | 64.0% | 63.0% | 63.6% | - |
| Operating margin | 15.5% | - | 18.7% | 18.5% | 14.3% | - | 19.7% | 19.4% | 18.5% | - |
| EBITDA margin | 22.1% | - | 24.9% | 24.4% | 20.3% | - | - | - | 20.6% | - |
| Net margin | 12.4% | - | 14.2% | 14.7% | 11.1% | - | 15.2% | 15.2% | 15.0% | - |
| Free cash flow margin | 6.9% | - | - | - | 2.2% | - | - | - | 0.7% | - |
| FCF / Net income | 0.56 | - | - | - | 0.19 | - | - | - | 0.05 | - |
| R&D / Revenue | 6.9% | - | 6.8% | 6.8% | 6.9% | - | 6.9% | 6.7% | 7.0% | - |
| SG&A / Revenue | 37.9% | - | 33.8% | 34.5% | 39.2% | - | 34.5% | 34.1% | 35.1% | - |
| Effective tax rate | 12.4% | - | 16.5% | 13.0% | 14.4% | - | 20.0% | 17.3% | 14.6% | - |
| Return on assets | 1.6% | - | 1.8% | 1.9% | 1.4% | - | 1.9% | 2.1% | 2.0% | - |
| Return on equity | 3.2% | - | 3.9% | 4.2% | 3.1% | - | 4.1% | 4.2% | 4.1% | - |
| Return on invested capital | 2.2% | - | 2.6% | 2.7% | 2.0% | - | 2.6% | 2.9% | 2.8% | - |
| Liquidity | ||||||||||
| Current ratio | 2.11 | 1.89 | 1.85 | 1.78 | 1.64 | 1.95 | 1.91 | 1.68 | 1.71 | 1.58 |
| Quick ratio | 1.25 | 1.21 | 1.13 | 1.06 | 1.00 | 1.32 | 1.22 | 0.95 | 0.99 | 0.97 |
| Cash ratio | 0.46 | 0.51 | 0.44 | 0.33 | 0.29 | 0.48 | 0.50 | 0.27 | 0.34 | 0.38 |
| Leverage | ||||||||||
| Debt / Equity | 0.62 | 0.66 | 0.68 | 0.70 | 0.69 | 0.59 | 0.66 | 0.51 | 0.56 | 0.59 |
| Debt / Assets | 0.31 | 0.31 | 0.32 | 0.32 | 0.31 | 0.28 | 0.30 | 0.26 | 0.27 | 0.27 |
| Debt / EBITDA | 10.67 | - | 9.86 | 10.11 | 12.07 | - | - | - | 10.02 | - |
| Interest coverage | 6.6x | - | 7.2x | 11.6x | - | - | - | - | - | - |
| Equity multiplier | 2.01 | 2.13 | 2.16 | 2.19 | 2.20 | 2.08 | 2.18 | 1.98 | 2.06 | 2.15 |
| Liabilities / Assets | 0.50 | 0.53 | 0.54 | 0.54 | 0.55 | 0.52 | 0.54 | 0.49 | 0.51 | 0.53 |
| Efficiency | ||||||||||
| Asset turnover | 0.13 | - | 0.13 | 0.13 | 0.13 | - | 0.13 | 0.14 | 0.13 | - |
| Inventory turnover | 0.41 | - | 0.41 | 0.41 | 0.42 | - | 0.37 | 0.40 | 0.38 | - |
| Days sales outstanding | 217d | - | 220d | 237d | 246d | - | 248d | 244d | 242d | - |
| Days inventory outstanding | 895d | - | 889d | 885d | 878d | - | 977d | 918d | 960d | - |
| Days payable outstanding | 263d | - | 248d | 241d | 252d | - | 247d | 237d | 238d | - |
| Cash conversion cycle | 849d | - | 860d | 881d | 873d | - | 978d | 924d | 964d | - |
| Valuation | ||||||||||
| P / E | 170.3x | - | 166.5x | 172.8x | 220.3x | - | 167.3x | 159.0x | 174.6x | - |
| P / B | 5.5x | - | 6.6x | 7.2x | 6.9x | - | 6.9x | 6.6x | 7.2x | - |
| P / S | 21.1x | - | 23.6x | 25.4x | 24.5x | - | 25.4x | 24.2x | 26.3x | - |
| EV / EBITDA | 103.8x | - | 102.6x | 112.7x | 130.8x | - | - | - | 135.6x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 2.6% | - | 10.2% | 11.1% | 11.9% | - | 11.9% | 8.5% | 9.7% | - |
| Revenue CAGR (3y) | 8.0% | - | 10.6% | 10.3% | 11.1% | - | 9.7% | 8.1% | 9.9% | - |
| Revenue CAGR (5y) | 8.8% | - | 10.1% | 16.9% | 10.3% | - | 8.9% | 8.2% | 8.3% | - |
| Gross profit growth (YoY) | 1.8% | - | 9.5% | 12.4% | 12.3% | - | 11.4% | 7.4% | 10.5% | - |
| Operating income growth (YoY) | 11.8% | - | 4.6% | 5.9% | -13.9% | - | 16.5% | 8.9% | 32.2% | - |
| Net income growth (YoY) | 13.9% | - | 3.0% | 7.2% | -17.0% | - | 20.5% | 11.8% | 33.1% | - |
| EPS growth (YoY) | 14.2% | - | 2.8% | 7.0% | -17.6% | - | 20.0% | 10.9% | 33.1% | - |
| EPS CAGR (3y) | 7.8% | - | 1.2% | 10.0% | 26.2% | - | 23.7% | 11.4% | 37.4% | - |
| EPS CAGR (5y) | 19.6% | - | 6.4% | - | 5.4% | - | 11.9% | 11.2% | 13.5% | - |
| FCF growth (YoY) | 226.8% | - | - | - | 243.2% | - | - | - | -88.3% | - |
| FCF CAGR (5y) | 2.4% | - | - | - | -22.3% | - | - | - | -28.0% | - |
| Book value growth (YoY) | 9.8% | 8.7% | 8.1% | 7.2% | 9.2% | 11.0% | 12.5% | 13.8% | 13.5% | 11.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$34.59B totalMed Surg And Neurotechnology$15.65B · 45.2%
Orthopaedics And Spine$9.47B · 27.4%
Orthopaedics$9.47B · 27.4%
Product / service
$25.12B totalMedical$4.20B · 16.7%
Traumaand Extremities$3.95B · 15.7%
Endoscopy$3.81B · 15.2%
Instruments$3.18B · 12.7%
Knees$2.66B · 10.6%
Neuro Cranial$2.48B · 9.9%
Neurovascular$1.97B · 7.8%
Hips$1.86B · 7.4%
Other Orthopaedics$815.00M · 3.2%
Spine$185.00M · 0.7%
Geographic
$21.76B totalUS$12.30B · 56.6%
Non Us$3.34B · 15.4%
EMEA$3.18B · 14.6%
Asia Pacific$2.16B · 9.9%
Other Foreign Countries$765.00M · 3.5%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing STRYKER CORP against the 5 most active filers in the same SIC group.
Dividends
$3.44/share trailing 12 months · +4.9% YoY
| Ex-date | Per share |
|---|---|
| Mar 31, 2026 | $0.8800 |
| Dec 31, 2025 | $0.8800 |
| Sep 30, 2025 | $0.8400 |
| Jun 30, 2025 | $0.8400 |
| Mar 31, 2025 | $0.8400 |
| Dec 31, 2024 | $0.8400 |
| Sep 30, 2024 | $0.8000 |
| Jun 28, 2024 | $0.8000 |
| Mar 27, 2024 | $0.8000 |
| Dec 28, 2023 | $0.8000 |
| Sep 28, 2023 | $0.7500 |
| Jun 29, 2023 | $0.7500 |
| Mar 30, 2023 | $0.7500 |
| Dec 29, 2022 | $0.7500 |
| Sep 29, 2022 | $0.6950 |
| Jun 29, 2022 | $0.6950 |
| Mar 30, 2022 | $0.6950 |
| Dec 30, 2021 | $0.6950 |
| Sep 29, 2021 | $0.6300 |
| Jun 29, 2021 | $0.6300 |
| Mar 30, 2021 | $0.6300 |
| Dec 30, 2020 | $0.6300 |
| Sep 29, 2020 | $0.5750 |
| Jun 29, 2020 | $0.5750 |